Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
P/S ratio for Novavax, Inc. (NVAX)
P/S ratio as of 2023: 0.49
According to Novavax, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.49. At the end of 2022 the company had a P/S ratio of 0.50.
P/S ratio history for Novavax, Inc. from 1996 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 0.49 |
| 2022 | 0.50 |
| 2021 | 9.29 |
| 2020 | 13.49 |
| 2019 | 5.14 |
| 2018 | 19.84 |
| 2017 | 11.64 |
| 2016 | 22.22 |
| 2015 | 60.70 |
| 2014 | 43.68 |
| 2013 | 41.53 |
| 2012 | 11.28 |
| 2011 | 9.75 |
| 2010 | 742.23 |
| 2009 | 700.23 |
| 2008 | 121.10 |
| 2007 | 134.48 |
| 2006 | 51.36 |
| 2005 | 22.28 |
| 2004 | 14.57 |
| 2003 | 15.20 |
| 2002 | 4.23 |
| 2001 | 13.28 |
| 2000 | 65.31 |
| 1999 | 68.02 |
| 1998 | 34.40 |
| 1997 | 116.67 |
| 1996 | 348.32 |